Sarepta Therapeutics (SRPT) Stocktwits Mentions Statistics 2024

20 11.1%

1W 67.2% 1M 122.2% 3M 185.7%

Est. daily mentions on Stocktwits.

Similar companies

Company		Stocktwits Mentions
	Amgen AMGN	20 78%
	Gilead Sciences GILD	5 16.7%
	Catalyst Pharmaceuticals CPRX	4 42.9%
	Inovio Pharmaceuticals INO	55 37.5%
	Anavex Life Sciences AVXL	62 5.1%

Month over Month

Est. daily mentions on Stocktwits.

Oct 2024	14	88.5%
Sep 2024	8	48.1%
Aug 2024	15	105.4%
Jul 2024	7	78.3%
Jun 2024	33

How often is Sarepta Therapeutics mentioned on StockTwits?

Sarepta Therapeutics was mentioned an estimated 20 times in discussions on StockTwits yesterday.

Analyzing Stocktwits Mentions, how is Sarepta Therapeutics performing compared to its industry peers?

Sarepta Therapeutics underperforms its industry peers when it comes to Stocktwits Mentions, ranking in the 15th percentile.

What does a high frequency of StockTwits mentions indicate for Sarepta Therapeutics' market sentiment?

A high frequency of mentions on StockTwits for Sarepta Therapeutics could indicate strong market interest or sentiment towards the company. It often reflects the trading community's engagement with Sarepta Therapeutics' stock, potentially signaling bullish or bearish trends based on the context of the discussions.

How often does AltIndex update information on Sarepta Therapeutics' mentions on StockTwits?

AltIndex updates the data on Sarepta Therapeutics' mentions on StockTwits daily. This frequent update schedule ensures that investors have access to the most current insights into market sentiment and discussion dynamics related to Sarepta Therapeutics' on the platform.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.